Beaten-down biotech Clovis Oncology (CLVS +32%) spikes on increased volume in apparent response to two block trades larger than 19K shares.
Share were down ~88% this year before today’s action.
The company plans to file a U.S. marketing application this quarter for PARP inhibitor Rubraca (rucaparib) for BRCA-mutated prostate cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.